Actively Recruiting
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Led by Glaukos Corporation · Updated on 2026-02-27
250
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.
CONDITIONS
Official Title
Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signs of Demodex blepharitis in at least one eye
- Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye
You will not qualify if you...
- Presence of eczema or dermatitis in the ocular region of either eye
- Use of lid hygiene products within 14 days of Screening
- Active ocular infection or inflammation, other than blepharitis, in either eye at Screening
- Women who are pregnant, planning a pregnancy, or nursing
- Use of an investigational drug or device within 30 days prior to Screening or concurrent enrollment in another investigational trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Glaukos Clinical Study Site
Newport Beach, California, United States, 92663
Actively Recruiting
Research Team
S
Study Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here